{"denoms":[{"counts":[{"groupId":"BG000","value":"397"},{"groupId":"BG001","value":"400"},{"groupId":"BG002","value":"797"}],"units":"Participants"}],"groups":[{"description":"Neoadjuvant: Prior to surgery, participants receive up to 4 cycles (cycle length: 3 weeks) of pembrolizumab \\[200 mg, intravenous (IV); given on cycle day 1\\] in combination with platinum doublet neoadjuvant chemotherapy (NAC), consisting of cisplatin \\[75 mg/m\\^2, IV; given on cycle day 1\\] and either Gemcitabine \\[1000 mg/m\\^2, IV; given on cycle days 1 and 8\\] or Pemetrexed \\[500 mg/m\\^2, IV; given on cycle day 1\\].\n\nAdjuvant: 4-12 weeks following surgery, participants receive 13 cycles (cycle length: 3 weeks) of pembrolizumab \\[200 mg, IV; given on cycle day 1\\].","id":"BG000","title":"NAC + Neoadjuvant/Adjuvant Pembrolizumab"},{"description":"Neoadjuvant: Prior to surgery, participants receive up to 4 cycles (cycle length: 3 weeks) of placebo \\[normal saline, IV; given on cycle day 1\\] in combination with platinum doublet NAC, consisting of cisplatin \\[75 mg/m\\^2, IV; given on cycle day 1\\] and either Gemcitabine \\[1000 mg/m\\^2, IV; given on cycle days 1 and 8\\] or Pemetrexed \\[500 mg/m\\^2, IV; given on cycle day 1\\].\n\nAdjuvant: 4-12 weeks following surgery, participants receive 13 cycles (cycle length: 3 weeks) of placebo \\[normal saline, IV; given on cycle day 1\\].","id":"BG001","title":"NAC + Neoadjuvant/Adjuvant Placebo"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"8.5","value":"62.7"},{"groupId":"BG001","spread":"8.1","value":"63.6"},{"groupId":"BG002","spread":"8.3","value":"63.1"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"118"},{"groupId":"BG001","value":"116"},{"groupId":"BG002","value":"234"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"279"},{"groupId":"BG001","value":"284"},{"groupId":"BG002","value":"563"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"70"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"329"},{"groupId":"BG001","value":"333"},{"groupId":"BG002","value":"662"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"32"},{"groupId":"BG001","value":"33"},{"groupId":"BG002","value":"65"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"124"},{"groupId":"BG001","value":"125"},{"groupId":"BG002","value":"249"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"16"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"250"},{"groupId":"BG001","value":"239"},{"groupId":"BG002","value":"489"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"13"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"29"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"171"},{"groupId":"BG001","value":"173"},{"groupId":"BG002","value":"344"}],"title":"Squamous"},{"measurements":[{"groupId":"BG000","value":"226"},{"groupId":"BG001","value":"227"},{"groupId":"BG002","value":"453"}],"title":"Non-Squamous"}]}],"description":"Participants were classified according to tumor histology: Squamous or Non-squamous.","paramType":"COUNT_OF_PARTICIPANTS","title":"Histology","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"118"},{"groupId":"BG001","value":"121"},{"groupId":"BG002","value":"239"}],"title":"Stage II"},{"measurements":[{"groupId":"BG000","value":"279"},{"groupId":"BG001","value":"279"},{"groupId":"BG002","value":"558"}],"title":"Stage III"}]}],"description":"Participants were categorized by NSCLC stage: Stage II or Stage III. The lower the lung cancer stage, the less the cancer has spread. NSCLC stages can range from I to IV.","paramType":"COUNT_OF_PARTICIPANTS","title":"Overall Cancer Staging","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"132"},{"groupId":"BG001","value":"134"},{"groupId":"BG002","value":"266"}],"title":"TPS>=50%"},{"measurements":[{"groupId":"BG000","value":"265"},{"groupId":"BG001","value":"266"},{"groupId":"BG002","value":"531"}],"title":"TPS<50%"}]}],"description":"Participants were assessed for their PD-L1 tumor expression status by immunohistochemistry assay using tumor tissue from an archival or newly obtained biopsy. Participants with a tumor proportion score (TPS) were classified as follows: ≥50% = PD-L1 strongly positive; 1-49% = PD-L1 weakly positive; and \\<1% = PD-L1 negative.","paramType":"COUNT_OF_PARTICIPANTS","title":"PD-L1 Expression Level (50% cutoff)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"123"},{"groupId":"BG001","value":"121"},{"groupId":"BG002","value":"244"}],"title":"East-Asia"},{"measurements":[{"groupId":"BG000","value":"274"},{"groupId":"BG001","value":"279"},{"groupId":"BG002","value":"553"}],"title":"Non-East Asia"}]}],"description":"Participants were categorized according to geographic region of site: Non-East Asia and East Asia.","paramType":"COUNT_OF_PARTICIPANTS","title":"Region","unitOfMeasure":"Participants"}]}